{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:17:44Z","timestamp":1781212664981,"version":"3.54.1"},"reference-count":20,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["21K20714"],"award-info":[{"award-number":["21K20714"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Gentamicin is an aminoglycoside antibiotic that is mostly used for the pediatric population. While the pediatric population is classified into neonates, infants, children, and adolescents based on developmental or maturational changes, infants are often overlooked in research. Three infant cases receiving gentamicin are presented to illustrate the pharmacokinetics and optimum dosage of gentamicin. Three infant patients received gentamicin (5.6\u20137.5 mg\/kg\/day) for urinary tract infections (UTIs) or bacteremia caused by Enterobacter aerogenes. The trough (Cmin) and peak (Cpeak) concentrations of gentamicin were 0.2\u20131.8 and 8.9 mg\/L, respectively. The Cmin of a patient receiving gentamicin at 9.0 mg\/kg\/day was 3.3 mg\/L, and the patient showed a decrease in urinary volume. The other two patients fully recovered from the infection and did not experience any adverse events. Additionally, we reviewed three studies regarding infant patients receiving gentamicin. The studies used gentamicin therapy for Gram-negative pathogen infections and UTIs caused by Escherichia coli and Enterococcus faecalis. The Cmin and Cpeak of patients receiving gentamicin at 2.2\u20137.5 mg\/kg\/day were 0.58\u20132.15 mg\/kg and 4.67\u20138.88 mg\/L, respectively. All patients were cured without any adverse events. Gentamicin dosages below 7.5 mg\/kg\/day may be effective and safe for use in infant patients. However, the optimal dosing regimen of gentamicin in infant patients is controversial, and limited data are available.<\/jats:p>","DOI":"10.3390\/ijerph192215360","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T03:05:11Z","timestamp":1668999911000},"page":"15360","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gentamicin Pharmacokinetics and Optimal Dosage in Infant Patients: A Case Report and Literature Review"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5272-9560","authenticated-orcid":false,"given":"Hideo","family":"Kato","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Mie University Hospital, Tsu 514-8507, Japan"},{"name":"Department of Clinical Pharmaceutics, Division of Clinical Medical Science, Mie University Graduate School of Medicine, Tsu 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Hagihara","sequence":"additional","affiliation":[{"name":"Department of Molecular Epidemiology and Biomedical Sciences, Aichi Medical University Hospital, Nagakute 480-1195, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mie University Hospital, Tsu 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6445-4410","authenticated-orcid":false,"given":"Takuya","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mie University Hospital, Tsu 514-8507, Japan"},{"name":"Department of Clinical Pharmaceutics, Division of Clinical Medical Science, Mie University Graduate School of Medicine, Tsu 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1101\/cshperspect.a027029","article-title":"Aminoglycosides: An Overview","volume":"6","author":"Krause","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2125.2009.03591.x","article-title":"What is the right dose for children?","volume":"70","author":"Cella","year":"2010","journal-title":"Br. J. Clin. Pharm."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1460-9592.2011.03536.x","article-title":"Tips and traps analyzing Pediatric PK data","volume":"21","author":"Anderson","year":"2011","journal-title":"Paediatr. Anaesth."},{"key":"ref_4","unstructured":"U.S. FDA (2022, August 01). Guidance for Industry: General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products, Available online: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm072114.pdf."},{"key":"ref_5","unstructured":"European Medicines Agency (2022, November 01). Note for Guidance on Clinical Investigation of Medicinal Products in the Paediatric Population (CPMP\/ICH\/2711\/99), Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-1.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s13318-021-00708-x","article-title":"Gentamicin Dosing in Neonates with Normal Renal Function: Trough and Peak Levels","volume":"46","author":"Davies","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40262-019-00813-w","article-title":"Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature","volume":"59","author":"Hartman","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_8","first-page":"47","article-title":"Pharmacokinetics study on gentamicin intravenous drip infusion in children","volume":"36","author":"Sunagawa","year":"1983","journal-title":"Jpn. J. Antibiot."},{"key":"ref_9","first-page":"549","article-title":"Clinicl and pharmacokinetic studies of gentamicin in intravenous drip infusion to children","volume":"41","author":"Sakata","year":"1998","journal-title":"Jpn. J. Antibiot."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00246-010-9660-6","article-title":"Gentamicin dosing for pediatric patients with congenital heart disease","volume":"31","author":"Moffett","year":"2010","journal-title":"Pediatr. Cardiol."},{"key":"ref_11","first-page":"357","article-title":"Results of a questionnaire survey on the use of gentamicin sulfate injection","volume":"87","author":"Ohnishi","year":"2013","journal-title":"J. Jpn. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5863\/1551-6776-20.2.119","article-title":"Extended-interval gentamicin dosing in achieving therapeutic concentrations in malaysian neonates","volume":"2","author":"Low","year":"2015","journal-title":"J. Pediatr. Pharmacol. Therapeut."},{"key":"ref_13","first-page":"485","article-title":"Clinical pharmacokinetics in optimal gentamicin dosing regimen in neonates","volume":"9","author":"Rakonjac","year":"2014","journal-title":"Cent. Eur. J. Med."},{"key":"ref_14","unstructured":"Chisholm-Burns, M. (2016). Pharmacotherapy Principles & Practice, McGraw-Hill Medical. [4th ed.]."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijantimicag.2016.10.022","article-title":"Determinants of gentamicin concentrations in critically ill patients: A population pharmacokinetic analysis","volume":"49","author":"Hodiamont","year":"2017","journal-title":"Int. J. Antimicrob. Agent."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jiac.2020.01.007","article-title":"Clinical audit of gentamicin use by Bayesian pharmacokinetic approach in critically ill children","volume":"26","author":"Sridharan","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"ref_17","unstructured":"Chambers, H.F. (2001). Goodman and Gillman\u2019s the Pharmacological Basis of Therapeutics, McGraw-Hill Professional; Medical."},{"key":"ref_18","first-page":"CD005091","article-title":"One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates","volume":"12","author":"Rao","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1128\/AAC.03464-14","article-title":"Population pharmacokinetics of gentamicin and dosing optimization for infants","volume":"59","author":"Garcia","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13052-021-01114-4","article-title":"Optimizing gentamicin dosing in different pediatric age groups using population pharmacokinetics and Monte Carlo simulation","volume":"47","author":"Ghoneim","year":"2021","journal-title":"Ital. J. Pediatr."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/22\/15360\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:22:35Z","timestamp":1760145755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/22\/15360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":20,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["ijerph192215360"],"URL":"https:\/\/doi.org\/10.3390\/ijerph192215360","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]}}}